Natera Inc., a global leader in cell-free DNA and precision medicine, has announced the launch of the TEODOR trial, a Phase II, multicenter, randomized controlled trial aimed at optimizing neoadjuvant therapy in early-stage breast cancer. Sponsored by the Austrian Breast & Colorectal Cancer Study Group, the TEODOR trial seeks to assess the potential of replacing chemotherapy with endocrine therapy for women with hormone receptor-positive, HER2-negative breast cancer, who are endocrine responsive and test negative with Natera's Signatera test. The trial will enroll approximately 250 patients across 15 sites in Austria. The study's primary endpoint is the rate of neoadjuvant therapy response, with secondary endpoints including breast cancer recurrence and overall survival. Results from the trial are expected to be presented in the future.